Overall Score

Threat Of New Entrants

Low barriers to entry in biotech keep competitive pressure high.

SANA’s limited scale and negative profitability make it harder to build durable entry barriers.

Bargaining Power Of Suppliers

Specialized biotech inputs and clinical development dependencies can give suppliers leverage.

The company’s small scale limits its negotiating power with key vendors and research partners.

Bargaining Power Of Buyers

Customers and payers in biotech can be highly price-sensitive and concentrated.

SANA has no revenue yet, so it has no demonstrated pricing power with buyers.

Threat Of Substitutes

Alternative therapies and competing drug modalities can substitute for future products.

With no commercial products, SANA has not yet established differentiation that would reduce substitution risk.

Industry Rivalry

Biotech competition is intense, with many firms pursuing similar therapeutic targets and capital.

SANA’s negative returns and cash burn suggest it is competing in a crowded, capital-intensive field.